European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, multicentrická studie
PubMed
38471049
DOI
10.1200/jco.23.01647
Knihovny.cz E-zdroje
- MeSH
- bcr-abl fúzní proteiny genetika antagonisté a inhibitory MeSH
- chronická myeloidní leukemie * farmakoterapie genetika MeSH
- dospělí MeSH
- imatinib mesylát terapeutické užití MeSH
- indukce remise * MeSH
- inhibitory proteinkinas * terapeutické užití MeSH
- inhibitory tyrosinkinasy MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- prognóza MeSH
- pyrimidiny terapeutické užití MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- Geografické názvy
- Evropa MeSH
- Názvy látek
- bcr-abl fúzní proteiny MeSH
- imatinib mesylát MeSH
- inhibitory proteinkinas * MeSH
- inhibitory tyrosinkinasy MeSH
- pyrimidiny MeSH
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The European Stop Kinase Inhibitors (EURO-SKI) study is the largest clinical trial for investigating the cessation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in stable deep molecular remission (DMR). Among 728 patients, 434 patients (61%; 95% CI, 57 to 64) remained in major molecular response (MMR) at 6 months and 309 patients of 678 (46%; 95% CI, 42 to 49) at 36 months. Duration of TKI treatment and DMR before TKI stop were confirmed as significant factors for the prediction of MMR loss at 6 months. In addition, the type of BCR::ABL1 transcript was identified as a prognostic factor. For late MMR losses after 6 months, TKI treatment duration, percentage of blasts in peripheral blood, and platelet count at diagnosis were significant factors in multivariate analysis. For the entire study period of 36 months, multiple logistic regression models confirmed duration of treatment, blasts, and transcript type as independent factors for MMR maintenance. In addition to the duration of treatment, transcript type as well as blasts in peripheral blood at diagnosis should be considered as important factors to predict treatment-free remission.
Bergonié Cancer Institute INSERM UMR1312 Inserm University of Bordeaux Bordeaux France
Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf Aachen Germany
Centre Léon Bérard Lyon France
Department of Genetics and Pathology Laboratory Medicine Region Skåne Lund Sweden
Department of Haematology Odense University Hospital Odense Denmark
Department of Haematology Oncology and Radiation Physics Skåne University Hospital Lund Sweden
Department of Hematology Amsterdam UMC Location VUMC Amsterdam the Netherlands
Department of Medical Science and Division of Hematology University Hospital Uppsala Sweden
Division of Clinical Genetics Department of Laboratory Medicine Lund University Lund Sweden
Faculdade de Medicina Universidade Católica Portuguesa Lisbon Portugal
Groupe Fi LMC Centre Léon Bérard Lyon France
Hematology Department Institut Bergonié Bordeaux France
Hospital 12 de Octubre CNIO i 12 Department of Medicine Univ Complutense Madrid Spain
ICAN Digital Precision Cancer Medicine Flagship Helsinki Finland
Innere Medizin 3 Diakonie Klinikum Schwäbisch Hall Germany
Institute of Hematology and Blood Transfusion Prague Czech Republic
Klinik für Innere Medizin 2 Universitätsklinikum Jena Jena Germany
Laboratory of Hematology University Hospital of Bordeaux Hôpital Haut Lévêque Pessac France
Laikon General Hospital National and Kapodistrian University of Athens Athens Greece
Onkologische Schwerpunktpraxis Heilbronn Heilbronn Germany
Service d'Hématologie Adulte and INSERM UMR 1160 Hôpital Saint Louis Paris France
Citace poskytuje Crossref.org
